嗜酸性粒细胞引导的糖皮质激素治疗用于慢阻肺急性加重住院患者(CORTICO-COP):多中心随机对照开放标签非劣效试验
该多中心随机对照开放标签非劣效试验纳入丹麦三家大学附属医院因慢阻肺急性加重住院的患者,比较基于血嗜酸性粒细胞计数的引导治疗与标准全身糖皮质激素治疗。结果显示引导组14天内存活且出院天数非劣效于标准组,且全身糖皮质激素暴露时间显著缩短,但不能完全排除部分次要结局的危害。
要点
- 嗜酸性粒细胞引导治疗在14天存活且出院天数上非劣效于标准治疗。
- 引导组全身糖皮质激素中位疗程为2天,显著短于标准组的5天。
- 30天治疗失败率和死亡率两组无显著差异,但需更大样本评估安全性。
核心结论
- 嗜酸性粒细胞引导治疗在14天存活且出院天数上非劣效于标准治疗,并缩短全身糖皮质激素暴露时间。
- 但不能完全排除部分次要结局指标存在危害的可能性。
研究设计与样本
- 多中心、随机、对照、开放标签、非劣效试验,在丹麦三家大学附属医院的呼吸科进行。
- 随机1:1分配至嗜酸性粒细胞引导组或标准全身糖皮质激素治疗组,两组均第1天静脉给予甲泼尼龙80 mg。
主要发现
- 意向性治疗分析纳入引导组159例和对照组159例。
关键数值与推荐
- 两组第1天均接受甲泼尼龙80 mg静脉注射。
临床怎么用
- 该策略在14天存活且出院天数上非劣效于标准5天疗程,但需关注次要结局的潜在危害。
- 实施时需结合患者个体情况和最新证据,并注意该研究不能完全排除部分次要结局的危害。
局限性
- 开放标签设计,研究者和患者均知晓分组。
- 样本量有限(每组159例),可能不足以评估罕见不良事件或次要结局的差异。
- 研究仅在丹麦三家医院进行,外推性需谨慎。
- 作者指出需要更大规模研究来确定该策略的完整安全性特征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment with systemic corticosteroids in patients with acute exacerbations of chronic obstructive pulmonary disease (COPD) is associated with debilitating adverse effects. Therefore, strategies to reduce systemic corticosteroid exposure are urgently required and might be offered by a personalised biomarker-guided approach to treatment. The aim of this study was to determine whether an algorithm based on blood eosinophil counts could safely reduce systemic corticosteroid exposure in patients admitted to hospital with acute exacerbations of COPD. METHODS: We did a multicentre, randomised, controlled, open-label, non-inferiority trial at the respiratory departments of three different university-affiliated hospitals in Denmark. Eligible participants were patients included within 24h of admission to the participating sites, aged at least 40 years, with known airflow limitation (defined as a post-bronchodilator FEV1/forced vital capacity [FVC] ratio ≤0·70) and a specialist-verified diagnosis of COPD, who were designated to start on systemic corticosteroids by the respiratory medicine physician on duty. We randomly assigned patients (1:1) to either eosinophil-guided therapy or standard therapy with systemic corticosteroids. Both investigators and patients were aware of the group assignment. All patients received 80 mg of intravenous methylprednisolone on the first day. The eosinophil-guided group were from the second day given 37·5 mg of prednisolone oral tablet daily (for a maximum of up to 4 days) on days when their blood eosinophil count was at least 0·3 × 109 cells per L. On days when the eosinophil count was lower, prednisolone was not administered. If a patient was discharged during the treatment period, a treatment based on the last measured eosinophil count was prescribed for the remaining days within the 5-day period (last observation carried forward). The control group received 37·5 mg of prednisolone tablets daily from the second day for 4 days. The primary outcome was the number of days alive and out of hospital within 14 days after recruitment, assessed by intention to treat (ITT). Secondary outcomes included treatment failure at day 30 (ie, recurrence of acute exacerbation of COPD resulting in emergency room visits, admission to hospital, or need to intensify pharmacological treatment), number of deaths on day 30, and duration of treatment with systemic corticosteroids. The non-inferiority margin was 1·2 days (SD 3·8). This trial is registered at ClinicalTrials.gov, number NCT02857842, and was completed in January, 2019. FINDINGS: Between Aug 3, 2016, and Sept 30, 2018, 159 patients in the eosinophil-guided group and 159 patients in the control group were included in the ITT analyses. There was no between-group difference for days alive and out of hospital within 14 days after recruitment: mean 8·9 days (95% CI 8·3-9·6) in the eosinophil-guided group versus 9·3 days (8·7-9·9) in the control group (absolute difference -0·4, 95% CI -1·3 to 0·5; p=0·34). Treatment failure at 30 days occurred in 42 (26%) of 159 patients in the eosinophil-guided group and 41 (26%) of 159 in the control group (difference 0·6%, 95% CI -9·0 to 10·3; p=0·90). At 30 days nine patients (6%) of 159 in the eosinophil-guided group and six (4%) of 159 in the control group had died (difference 1·9%, 95% CI -2·8 to 6·5; p=0·43). Median duration of systemic corticosteroid therapy was lower in the eosinophil-guided group: 2 days (IQR 1·0 to 3·0) compared with 5 days (5·0 to 5·0) in the control group, p<0·0001. INTERPRETATION: Eosinophil-guided therapy was non-inferior compared with standard care for the number of days alive and out of hospital, and reduced the duration of systemic corticosteroid exposure, although we could not entirely exclude harm on some secondary outcome measures. Larger studies will help to determine the full safety profile of this strategy and its role in the management of COPD exacerbations. FUNDING: The Danish Regions Medical Fund and the Danish Council for Independent Research.
引用
- Sivapalan P, Lapperre TS, Janner J, et al. Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): a multicentre, randomised, controlled, open-label, non-inferiority trial. Lancet Respir Med. 2019. PMID: 31122894. doi:10.1016/S2213-2600(19)30176-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。